The role of progesterone in maternal and fetal medicine

Gynecological Endocrinology

Volumn 28, Issue 11, 2012, Pages 925-932

  Di Renzo, Gian Carlo ^a   Giardina, Irene ^a   Clerici, Graziano ^a   Mattei, Alberto ^a   Alajmi, Alia H ^a   Gerli, Sandro ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Maternal fetal medicine; Micronised progesterone; Preterm labour; Progesterone; Recurrent abortion

Indexed keywords

PROGESTERONE;

ABDOMINAL PAIN; ACNE; ARTHRALGIA; ARTICLE; ASTHMA; BACKACHE; BLOATING; CERVICAL LENGTH MEASUREMENT; CORPUS LUTEUM; DEPRESSION; DIZZINESS; DRUG SAFETY; FATIGUE; FETAL WELL BEING; FEVER; FIRST TRIMESTER PREGNANCY; FLU LIKE SYNDROME; GESTATIONAL AGE; HUMAN; IMMINENT ABORTION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LEG PAIN; LENGTH OF STAY; META ANALYSIS (TOPIC); MOOD CHANGE; MULTICENTER STUDY (TOPIC); MULTIPLE PREGNANCY; MYCOSIS; NAUSEA AND VOMITING; NERVOUSNESS; NEWBORN MORTALITY; PATIENT COMPLIANCE; PLACENTA CIRCULATION; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT ABORTION; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; SLEEP DISORDER; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

ABORTION, HABITUAL; FEMALE; HUMANS; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PROGESTINS;

EID: 84867491729     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.730576     Document Type: Article

References (62)

1. Di Renzo GC, Mattei A, Gojnic M, Gerli S. Progesterone and pregnancy. Curr Opin Obstet Gynecol 2005;17:598-600.
2. Nahoul K, Dehennin L, Scholler R. Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone. J Steroid Biochem 1987;26:241-249.
3. Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med 1998;217:369-378.
4. Fitzpatrick LA, Good A. Micronized progesterone: Clinical indications and comparison with current treatments. Fertil Steril 1999;72:389-397.
5. Di Renzo GC, Rosati A, Mattei A, Gojnic M, Gerli S. The changing role of progesterone in preterm labour. BJOG 2005;112 Suppl 1:57-60.
6. Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, Franceschetti F. Targeted drug delivery in gynaecology: The first uterine pass effect. Hum Reprod 1997;12:1073-1079.
7. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95:403-406.
8. Tita AT, Rouse DJ. Progesterone for preterm birth prevention: An evolving intervention. Am J Obstet Gynecol 2009;200:219-224.
9. Kurjak A, Chervenak FA. Management of preterm labor: Pharmacological and non-pharmacological aspects. Textbook of Perinatal Medicine. 2nd Edition. Cap. 130. UK, London: Informa Healthcare; 2006. pp 1394-1400.
10. Nakamura O. Children's immunology, what can we learn from animal studies (1): Decidual cells induce specific immune system of fetomaternal interface. J Toxicol Sci 2009;34 Suppl 2:SP331-SP339.
11. Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol 2009;80:91-99.
12. Szekeres-Bartho J. Progesterone-mediated immunomodulation in pregnancy: Its relevance to leukocyte immunotherapy of recurrent miscarriage. Immunotherapy 2009;1:873-882.
13. Raghupathy R. Manipulation of cytokine production profiles as a therapeutic approach for immunologic pregnancy loss. Indian J Biochem Biophys 2008;45:229-236.
14. Druckmann R, Druckmann MA. Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol 2005;97:389-396.
15. Szekeres-Bartho J, Par G, Dombay G, Smart YC, Volgyi Z. The antiabortive effect of progesterone-induced blocking factor in mice is manifested by modulating NK activity. Cell Immunol 1997;177:194-199.
16. Szekeres-Bartho J. Immunological relationship between the mother and the fetus. Int Rev Immunol 2002;21:471-495.
17. Daya S. Luteal support: Progestogens for pregnancy protection. Maturitas 2009;65 Suppl 1:S29-S34.
18. Walch KT, Huber JC. Progesterone for recurrent miscarriage: Truth and deceptions. Best Pract Res Clin Obstet Gynaecol 2008;22:375-389.
19. Liu J, Matsuo H, Laoag-Fernandez JB, Xu Q, Maruo T. The effects of progesterone on apoptosis in the human trophoblast-derived HTR-8/SV neo cells. Mol Hum Reprod 2007;13:869-874.
20. Devoto L, Kohen P, Muz A, Strauss JF 3rd. Human corpus luteum physiology and the luteal-phase dysfunction associated with ovarian stimulation. Reprod Biomed Online 2009;18 Suppl 2:19-24.
21. Ruddock NK, Shi SQ, Jain S, Moore G, Hankins GD, Romero R, Garfield RE. Progesterone, but not 17-α-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol 2008;199:391. e1-391.e7.
22. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008;CD003511.
23. Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: Evaluation and management. BMJ 2004;329:152-155.
24. Kalinka J, Szekeres-Bartho J. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. Am J Reprod Immunol 2005;53:166-171.
25. Czajkowski K, Sienko J, Mogilinski M, Bros M, Szczecina R, Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 2007;87:613-618.
26. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989;96:265-274.
27. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet Gynaecol 1989;96:275-280.
28. Walch K, Hefler L, Nagele F. Oral dydrogesterone treatment during the first trimester of pregnancy: The prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebocontrolled, parallel group trial. J Matern Fetal Neonatal Med 2005;18:265-269.
29. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, et al.; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 α-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-2385.
30. Di Renzo GC, Roura LC, Facchinetti F, Antsaklis A, Breborowicz G, Gratacos E, Husslein P, et al. Guidelines for the management of spontaneous preterm labor: Identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern Fetal Neonatal Med 2011;24:659-667.
31. Ferre F, Uzan M, Janssens Y, Tanguy G, Jolivet A, Breuiller M, Sureau C, Cedard L. Oral administration of micronized natural progesterone in late human pregnancy. Effects on progesterone and estrogen concentrations in the plasma, placenta, and myometrium. Am J Obstet Gynecol 1984;148:26-34.
32. Noblot G, Audra P, Dargent D, Faguer B, Mellier G. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991;40:203-209.
33. Baumbach J, Coonrod D, Shi SQ, Shi L, Balducci J, Garfield R. Inhibition of uterine contractility during pregnancy with various tocolytics alone or in combination with progesterone. Am J Obstet Gynecol 2011 (Abstract 26).
34. Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: A randomised controlled trial. Aust N Z J Obstet Gynaecol 2008;48:58-63.
35. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-424.
36. Cetingoz E, Cam C, Sakalli M, Karateke A, Celik C, Sancak A. Progesterone effects on preterm birth in high-risk pregnancies: A randomized placebocontrolled trial. Arch Gynecol Obstet 2011;283:423-429.
37. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: Effects of 17-α- hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453.e1-4; discussion 421.
38. Istwan N, Rhea D, Desh C, Barton JR, Barton LA, Sibai B. 17 α-hydroxyprogesterone caproate in women with previous preterm delivery: Does a previous term delivery influence effectiveness? Am J Obstet Gynecol 2011 (Abstract 27).
39. Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 α-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980;56:692-695.
40. Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): A multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011;38:272-280.
41. To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH. Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: A population-based prospective study. Ultrasound Obstet Gynecol 2006;27:362-367.
42. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: A secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:697-705.
43. Berghella V, Figueroa D, Szychowski JM, Owen J, Hankins GD, Iams JD, Sheffield JS, et al.; Vaginal Ultrasound Trial Consortium. 17-α- hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010;202:351.e1-351.e6.
44. American College of Obstetricians and Gynecologists (ACOG). Incidentally detected short cervical length. Committee Opinion No. 522. Obstet Gynecol 2012;119:879-882.
45. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-469.
46. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, et al.; PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: A multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18-31.
47. Campbell S. Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: Doing nothing is no longer an option. Ultrasound Obstet Gynecol 2011;38:1-9.
48. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, Da Fonseca E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: A systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012;206:124.e1-124.19.
49. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Soma-Pillay P, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: Primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:687-696.
50. Christian MS, Brent RL, Calda P. Embryo-fetal toxicity signals for 17α-hydroxyprogesterone caproate in high-risk pregnancies: A review of the non-clinical literature for embryo-fetal toxicity with progestins. J Matern Fetal Neonatal Med 2007;20:89-112.
51. Calda P. Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth. J Matern Fetal Neonatal Med 2009;22:540-542.
52. How HY, Sibai BM. Progesterone for the prevention of preterm birth: Indications, when to initiate, efficacy and safety. Ther Clin Risk Manag 2009;5:55-64.
53. Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ, Saltzman DH. Increased incidence of gestational diabetes in women receiving prophylactic 17α-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007;30:2277-2280.
54. O'Brien JM. 17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone should. Am J Obstet Gynecol 2011;204:e16-7; author reply e17.
55. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Swain M, et al.; National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Follow-up of children exposed in utero to 17 α-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007;110:865-872.
56. Combs CA, Maruel K, Garite T, Porto M. 17-hydroprogesterone for twin pregnancy: No reduction in prematurity or neonatal morbidity. Am J Obstet Gynecol 2011 (Abstract 11).
57. O'Brien JM, Lewis DF. Progestins for the prevention of spontaneous preterm birth: Review and implications of recent studies. J Reprod Med 2009;54:73-87.
58. Cahill AG, Odibo AO, Caughey AB, Stamilio DM, Hassan SS, Macones GA, Romero R. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: A decision and economic analysis. Am J Obstet Gynecol 2010;202:548.e1-8.
59. Werner EF, Han CS, Pettker CM, Buhimschi CS, Copel JA, Funai EF, Thung SF. Universal cervical-length screening to prevent preterm birth: A cost-effectiveness analysis. Ultrasound Obstet Gynecol 2011;38:32-37.
60. Berghella V. Society for Maternal-Fetal Medicine (SMFM). Progesterone and preterm birth prevention: Translating clinical trials data into clinical practice. SMFM clinical guideline. Am J Obstet Gynecol 2012 (In Press).
61. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, et al.; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 α-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454-461.
62. Combs CA, Garite T, Maurel K, Das A, Porto M; Obstetrix Collaborative Research Network. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: A doubleblind, randomized clinical trial. Am J Obstet Gynecol 2010;203:248. e1-248.e9.